Actinium Pharmaceuticals Q3 EPS $(0.37) Misses $(0.30) Estimate
Actinium Pharmaceuticals Q3 EPS $(0.37) Misses $(0.30) Estimate
actinium製藥第三季度每股收益$(0.37)低於$(0.30)的預期
Actinium Pharmaceuticals (AMEX:ATNM) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.30) by 23.33 percent. This is a 24.49 percent increase over losses of $(0.49) per share from the same period last year.
actinium製藥(美交所:ATNM)報告季度虧損爲每股$(0.37)，低於分析師共識預估$(0.30)的23.33%。相較於去年同期每股虧損$(0.49)，這是一項24.49%的增長。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。